Pharmaceuticals

Drug Development Drug Pricing Drug Approval Drug Safety Clinical Trials Weight Loss Drugs Prescription Drugs Biotechnology Drug Regulation Drug Manufacturing

3 ARTICLES

23h ago

Real‑World Data Show Fezolinetant Cuts Hot Flashes and Eases Mood Symptoms

Industry‑sponsored observational results indicate the drug’s clinical‑trial benefits appear in a broader patient group but do not prove cause and effect.

Stories older than 24h

3 ARTICLES

3d ago

Daraxonrasib Doubles Survival in Phase 3 Trial for Advanced Pancreatic Cancer

3 ARTICLES

last wk.

Eli Lilly Spends $3.8 Billion to Build Vaccine Business

4 ARTICLES

last wk.

Large Observational Studies Link GLP‑1 Drugs to Lower Cancer Rates and Slower Progression

10 ARTICLES

last wk.

Supreme Court Clears Path for Generic 'Skinny Labels' in Unanimous Hikma Ruling

4 ARTICLES

last wk.

Flu Drug Class Prevents Glycan Loss Linked to Cognitive Decline in People With HIV

4 ARTICLES

last wk.

CVS Caremark Reverses Exclusion and Adds Lilly’s Foundayo and Zepbound to Its Formulary

5 ARTICLES

last wk.

Lilly’s GLP‑1 Sales and PBM Coverage Fuel Record Quarter as Pipeline Logs Durable Wins

3 ARTICLES

2w ago

FDA Approves Xocova as First U.S. Post-Exposure COVID-19 Antiviral

12 ARTICLES

2w ago

Eli Lilly Rides Breakthrough Retatrutide Data and $4 Billion Vaccine Push to Record Highs

12 ARTICLES

2w ago

New Hepatitis B Drug Produces Functional Cure in About One in Five Patients

4 ARTICLES

2w ago

Novo Nordisk Narrows Gap With Lilly as Wegovy Pill Leads Early Oral Sales

3 ARTICLES

2w ago

MediWound Posts Weak Q1 but Reaffirms 2026 Revenue Target as BARDA Deal and Factory Upgrades Drive H2 Plan

3 ARTICLES

2w ago

Bernstein Raises UnitedHealth Target to $492 on Signs of Medicare Advantage Recovery

4 ARTICLES

2w ago

Concentrated Pharma ETF Outperforms but Carries Bigger Single-Stock Risk

46 ARTICLES

3w ago

White House Adds More Than 600 Generics to TrumpRx and Links Site to Cost Plus, Amazon and GoodRx

3 ARTICLES

3w ago

Jury Finds Takeda Liable for Delaying Amitiza Generics, Awards $885 Million

10 ARTICLES

3w ago

Supreme Court Rejects Drugmakers’ Appeals Over Medicare Price Talks

3 ARTICLES

3w ago

Gossamer Bio Hit With Investor Class Action After PROSERA Miss, With June 1 Lead‑Plaintiff Deadline

9 ARTICLES

4w ago

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

Pharmaceuticals

Real‑World Data Show Fezolinetant Cuts Hot Flashes and Eases Mood Symptoms

Daraxonrasib Doubles Survival in Phase 3 Trial for Advanced Pancreatic Cancer

Eli Lilly Spends $3.8 Billion to Build Vaccine Business

Large Observational Studies Link GLP‑1 Drugs to Lower Cancer Rates and Slower Progression

Supreme Court Clears Path for Generic 'Skinny Labels' in Unanimous Hikma Ruling

Flu Drug Class Prevents Glycan Loss Linked to Cognitive Decline in People With HIV

CVS Caremark Reverses Exclusion and Adds Lilly’s Foundayo and Zepbound to Its Formulary

Lilly’s GLP‑1 Sales and PBM Coverage Fuel Record Quarter as Pipeline Logs Durable Wins

FDA Approves Xocova as First U.S. Post-Exposure COVID-19 Antiviral

Eli Lilly Rides Breakthrough Retatrutide Data and $4 Billion Vaccine Push to Record Highs

Never miss stories about

Pharmaceuticals

New Hepatitis B Drug Produces Functional Cure in About One in Five Patients

Novo Nordisk Narrows Gap With Lilly as Wegovy Pill Leads Early Oral Sales

MediWound Posts Weak Q1 but Reaffirms 2026 Revenue Target as BARDA Deal and Factory Upgrades Drive H2 Plan

Bernstein Raises UnitedHealth Target to $492 on Signs of Medicare Advantage Recovery

Concentrated Pharma ETF Outperforms but Carries Bigger Single-Stock Risk

White House Adds More Than 600 Generics to TrumpRx and Links Site to Cost Plus, Amazon and GoodRx

Jury Finds Takeda Liable for Delaying Amitiza Generics, Awards $885 Million

Supreme Court Rejects Drugmakers’ Appeals Over Medicare Price Talks

Gossamer Bio Hit With Investor Class Action After PROSERA Miss, With June 1 Lead‑Plaintiff Deadline

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

Never miss stories about

Pharmaceuticals